Bench-to-bedside review: Sepsis, severe sepsis and septic shock - Does the nature of the infecting organism matter?

Critical Care

Volumn 12, Issue 3, 2008, Pages

  Gao, Hongmei ^a   Evans, Timothy W ^a   Finney, Simon J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL] 1 CYCLOHEXENE 1 CARBOXYLIC ACID ETHYL ESTER; ANTIINFECTIVE AGENT; CRX 526; DELTIBANT; DROTRECOGIN; ERITORAN; GINKGOLIDE B; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA RECEPTOR FUSION PROTEIN; UNCLASSIFIED DRUG; BACTERIAL DNA; CYTOKINE; ETHYL 6 (N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL)CYCLOHEX 1 ENE 1 CARBOXYLATE; ETHYL 6-(N-(2-CHLORO-4-FLUOROPHENYL)SULFAMOYL)CYCLOHEX-1-ENE-1-CARBOXYLATE; NITRIC OXIDE; SULFONAMIDE; TOLL LIKE RECEPTOR;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC SENSITIVITY; BACTERIAL VIRULENCE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; FUNGEMIA; GENE EXPRESSION PROFILING; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; GRAM POSITIVE INFECTION; HUMAN; IMMUNE RESPONSE; MICROBIAL IDENTIFICATION; MICROBIOLOGICAL EXAMINATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; BACTERIUM IDENTIFICATION; DRUG ANTAGONISM; IMMUNOLOGY; INTENSIVE CARE; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGY; PHYSIOLOGY;

BACTERIAL TYPING TECHNIQUES; CRITICAL CARE; CYTOKINES; DNA, BACTERIAL; HUMANS; NITRIC OXIDE; POLYMERASE CHAIN REACTION; SEPSIS; SIGNAL TRANSDUCTION; SULFONAMIDES; TOLL-LIKE RECEPTORS;

EID: 52449110340     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc6862     Document Type: Review

References (59)

1. Martin GS Mannino DM Eaton S Moss M The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 2003, 348:1546-1554. 10.1056/NEJMoa022139 12700374
2. Angus DC Linde-Zwirble WT Lidicker J Clermont G Carcillo J Pinsky MR Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002 11445675
3. Kaarlola A Pettila V Kekki P Quality of life six years after intensive care Intensive Care Med 2003, 29:1294-1299. 10.1007/s00134-003-1849-1 12879244
4. Perl TM Dvorak L Hwang T Wenzel RP Long-term survival and function after suspected gram-negative sepsis JAMA 1995, 274:338-345. 10.1001/ jama.274.4.338 7609265
5. Protecting 5 million lives from harm http://www.ihi.org/IHI/Programs/ Campaign/Campaign.htm
6. Dellinger RP Carlet JM Masur H Gerlach H Calandra T Cohen J Gea-Banacloche J Keh D Marshall JC Parker MM Ramsay G Zimmerman JL Vincent JL Levy MM Surviving Sepsis Campaign Management Guidelines Committee Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock Crit Care Med 2004, 32:858-873. 10.1097/ 01.CCM.0000117317.18092.E4 15090974
7. Pasteur L Septicemie puerperale Bulletin de l'Academie de Medecine 1879, 8:271-274.
8. Anonymous American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis Crit Care Med 1992, 20:864-874. 1597042
9. Labandeira-Rey M Couzon F Boisset S Brown EL Bes M Benito Y Barbu EM Vazquez V Höök M Etienne J Vandenesch F Bowden MG Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia Science 2007, 315:1130-1133. 10.1126/science.1137165 17234914
10. Gillet Y Issartel B Vanhems P Fournet JC Lina G Bes M Vandenesch F Piémont Y Brousse N Floret D Etienne J Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients Lancet 2002, 359:753-759. 10.1016/ S0140-6736(02)07877-7 11888586
11. Hamilton SM Bryant AE Carroll KC Lockary V Ma Y McIndoo E Miller LG Perdreau-Remington F Pullman J Risi GF Salmi DB Stevens DL In vitro production of panton-valentine leukocidin among strains of methicillin-resistant Staphylococcus aureus causing diverse infections Clin Infect Dis 2007, 45:1550-1558. 10.1086/523581 18190315
12. Ellington MJ Hope R Ganner M Ganner M East C Brick G Kearns AM Is Panton-Valentine leucocidin associated with the pathogenesis of Staphylococcus aureus bacteraemia in the UK? J Antimicrob Chemother 2007, 60:402-405. 17562682 10.1093/jac/dkm206
13. Opal SM Cohen J Clinical gram-positive sepsis: Does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 1999, 27:1608-1616. 10.1097/00003246-199908000-00039 10470773
14. Jabbari K Bernardi G Cytosine methylation and CpG, TpG (CpA) and TpA frequencies Gene 2004, 333:143-149. 10.1016/j.gene.2004.02.043 15177689
15. Hirschfeld M Ma Y Weis JH Vogel SN Weis JJ Cutting edge: Repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2 J Immunol 2000, 165:618-622. 10878331
16. Hashimoto M Imamura Y Yasuoka J Kotani S Kusumoto S Suda Y A novel cytokine-inducing glycolipid isolated from the lipoteichoic acid fraction of Enterococcus hirae ATCC 9790: A fundamental structure of the hydrophilic part Glycoconj J 1999, 16:213-221. 10.1023/A:1007076304254 10596896
17. Takeuchi O Hoshino K Akira S Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection J Immunol 2000, 165:5392-5396. 11067888
18. Bernheiden M Heinrich JM Minigo G Schutt C Stelter F Freeman M Golenbock D Jack RS LBP, CD14, TLR4 and the murine innate immune response to a peritoneal Salmonella infection J Endotoxin Res 2001, 7:447-450. 11753215
19. Sabroe I Prince LR Jones EC Horsburgh MJ Foster SJ Vogel SN Dower SK Whyte MK Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span J Immunol 2003, 170:5268-5275. 12734376
20. Abrahams VM Bole-Aldo P Kim YM Straszewski-Chavez SL Chaiworapongsa T Romero R Mor G Divergent trophoblast responses to bacterial products mediated by TLRs J Immunol 2004, 173:4286-4296. 15383557
21. Feezor RJ Oberholzer C Baker HV Novick D Rubinstein M Moldawer LL Pribble J Souza S Dinarello CA Ertel W Oberholzer A Molecular characterization of the acute inflammatory response to infections with Gram-negative versus Gram-positive bacteria Infect Immun 2003, 71:5803-5813. 201043 14500502 10.1128/IAI.71.10.5803-5813.2003
22. Ghosh TK Mickelson DJ Fink J Solberg JC Inglefield JR Hook D Gupta SK Gibson S Alkan SS Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses Cell Immunol 2006, 243:48-57. 10.1016/j.cellimm.2006.12.002 17250816
23. Iwadou H Morimoto Y Iwagaki H Sinoura S Chouda Y Kodama M Yoshioka T Saito S Yagi T Tanaka N Differential cytokine response in host repsonse in host defence mechanisms triggered by Gram-negative and Gram-positive bacteria, and the roles of gabexate mesilate, a synthetic protease inhibitor J Int Med Res 2002, 30:99-108. 12025532
24. Paul-Clark MJ McMaster SK Belcher E Sorrentino R Anandarajah J Fleet M Sriskandan S Mitchell JA Differential effects of Gram-positive versus Gram-negative bacteria on NOSII and TNFalpha in macrophages: Role of TLRs in synergy between the two Br J Pharmacol 2006, 148:1067-1075. 1752017 16783405 10.1038/sj.bjp.0706815
25. Bjerre A Brusletto B Hoiby EA Kierulf P Brandtzaeg P Plasma interferon-gamma and interleukin-10 concentrations in systemic meningococcal disease compared with severe systemic Gram-positive septic shock Crit Care Med 2004, 32:433-438. 10.1097/01.CCM.0000104950.52577.97 14758160
26. Mohamed MA Cunningham-Rundles S Dean CR Hammad TA Nesin M Levels of pro-inflammatory cytokines produced from cord blood in-vitro are pathogen dependent and increased in comparison to adult controls Cytokine 2007, 39:171-177. 10.1016/j.cyto.2007.07.004 17884557
27. Fisher CJ Jr Opal SM Dhainaut JF Stephens S Zimmerman JL Nightingale P Harris SJ Schein RM Panacek EA Vincent JL Foulke GE Warren EL Garrard C Park G Bodmer MW Cohen J Vanderlinden C Cross AS Sadoff JC Fisher CJ Panacek EA Warren EL Gorecki J Opal SM Dubin HG Garner C Kaye W Dhainaut JF Lanore JJ Mira JP Stephens S Harris SJ Bodmer MW Zimmerman J Dellinger RP Taylor RW Dahl S Nightingale P Shelly M Mortimer A Edwards JD Schein RMH Kett DH Quartin A Pena MA Vincent JL Bakker J Foulke GE Alberson TE Walby W Radcliffe J Garrard C Young D Mcquillam P Park G Cohen J Bellingham G Vanderlinden C Burman W Cross AS Sadoff JS Young L Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group Crit Care Med 1993, 21:318-327. 8440099
28. Leibovici L Samra Z Konigsberger H Drucker M Ashkenazi S Pitlik SD Long-term survival following bacteremia or fungemia Jama 1995, 274:807-812. 10.1001/jama.274.10.807 7650804
29. Brun-Buisson C Doyon F Carlet J Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group Am J Respir Crit Care Med 1996, 154:617-624. 8810595
30. Vincent JL Sakr Y Sprung CL Ranieri VM Reinhart K Gerlach H Moreno R Carlet J Le Gall JR Payen D Sepsis in European intensive care units: results of the SOAP study Crit Care Med 2006, 34:344-353. 10.1097/ 01.CCM.0000194725.48928.3A 16424713
31. Friedman G Silva E Vincent JL Has the mortality of septic shock changed with time Crit Care Med 1998, 26:2078-2086. 10.1097/ 00003246-199812000-00045 9875924
32. Wang JE Dahle MK McDonald M Foster SJ Aasen AO Thiemermann C Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism Shock 2003, 20:402-414. 10.1097/01.shk.0000092268.01859.0d 14560103
33. Wisplinghoff H Bischoff T Tallent SM Seifert H Wenzel RP Edmond MB Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 2004, 39:309-317. 10.1086/421946 15306996
34. Gudlaugsson O Gillespie S Lee K Berg Vande J Hu J Messer S Herwaldt L Pfaller M Diekema D Attributable mortality of nosocomial candidemia, revisited Clin Infect Dis 2003, 37:1172-1177. 10.1086/378745 14557960
35. Llewelyn MJ Cohen J Tracking the microbes in sepsis: Advancements in treatment bring challenges for microbial epidemiology Clin Infect Dis 2007, 44:1343-1348. 10.1086/515403 17443473
36. Sriskandan S Cohen J Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis Infect Dis Clin North Am 1999, 13:397-412. 10.1016/S0891-5520(05)70082-9 10340174
37. Fisher CJ Jr Agosti JM Opal SM Lowry SF Balk RA Sadoff JC Abraham E Schein RM Benjamin E Treatment of septic shock with the tumor necrosis factor receptor:FC fusion protein. The Soluble TNF Receptor Sepsis Study Group N Engl J Med 1996, 334:1697-1702. 10.1056/NEJM199606273342603 8637514
38. Cohen J Carlet J INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group Crit Care Med 1996, 24:1431-1440. 10.1097/00003246-199609000-00002 8797612
39. Dhainaut JF Tenaillon A Le Tulzo Y Schlemmer B Solet JP Wolff M Holzapfel L Zeni F Dreyfuss D Mira JP Devathaire F Guinot P Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group Crit Care Med 1994, 22:1720-1728. 7956274
40. Fein AM Bernard GR Criner GJ Fletcher EC Good JT Jr Knaus WA Levy H Matuschak GM Shanies HM Taylor RW Rodell TC Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group Jama 1997, 277:482-487. 10.1001/jama.277.6.482 9020273
41. Fisher CJ Jr Dhainaut JF Opal SM Pribble JP Balk RA Slotman GJ Iberti TJ Rackow EC Shapiro MJ Greenman RL et al Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group Jama 1994, 271:1836-1843. 10.1001/jama.271.23.1836 8196140
42. Anonymous The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin Arch Intern Med 1994, 154:2484-2491. 10.1001/ archinte.154.21.2484 7979845
43. Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW Fisher CJ Jr Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001, 344:699-709. 10.1056/ NEJM200103083441001 11236773
44. Opal SM Garber GE LaRosa SP Maki DG Freebairn RC Kinasewitz GT Dhainaut JF Yan SB Williams MD Graham DE Nelson DR Levy H Bernard GR Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated) Clin Infect Dis 2003, 37:50-58. 10.1086/375593 12830408
45. Ii M Matsunaga N Hazeki K Nakamura K Takashima K Seya T Hazeki O Kitazaki T Iizawa Y A novel cyclohexene derivative, ethyl (6R -6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling Mol Pharmacol 2006, 69:1288-1295. 10.1124/mol.105.019695 16373689
46. Yamada M Ichikawa T Ii M Sunamoto M Itoh K Tamura N Kitazaki T Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: Synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate J Med Chem 2005, 48:7457-7467. 10.1021/jm050623t 16279805
47. Sha T Sunamoto M Kitazaki T Sato J Ii M Iizawa Y Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model Eur J Pharmacol 2007, 571:231-239. 10.1016/j.ejphar.2007.06.027 17632100
48. A Study of the Safety and Efficacy of TAK-242 in Subjects With Sepsis-Induced Cardiovascular and Respiratory Failure http://www.clinicaltrials.gov/ct2/show/NCT00633477?term= NCT00633477&rank=1
49. A Study To Evaluate Efficacy & Safety Of TAK-242 In Adults With Severe Sepsis http://www.clinicaltrials.gov/ct2/show/NCT00143611?term= NCT00143611&rank=1
50. Mullarkey M Rose JR Bristol J Kawata T Kimura A Kobayashi S Przetak M Chow J Gusovsky F Christ WJ Rossignol DP Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist J Pharmacol Exp Ther 304:1093-1102. 12604686 10.1124/ jpet.102.044487
51. Lynn M Rossignol DP Wheeler JL Kao RJ Perdomo CA Noveck R Vargas R D'Angelo T Gotzkowsky S McMahon FG Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia J Infect Dis 2003, 187:631-639. 10.1086/367990 12599080
52. ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis http://www.clinicaltrials.gov/ct2/ results?term=NCT00334828
53. Fort MM Mozaffarian A Stöver AG Correia Jda S Johnson DA Crane RT Ulevitch RJ Persing DH Bielefeldt-Ohmann H Probst P Jeffery E Fling SP Hershberg RM A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease J Immunol 2005, 174:6416-6423. 15879143
54. Kuroishi T Tanaka Y Sakai A Sugawara Y Komine K Sugawara S Human parotid saliva contains soluble toll-like receptor (TLR) 2 and modulates TLR2-mediated interleukin-8 production by monocytic cells Mol Immunol 2007, 44:1969-1976. 10.1016/j.molimm.2006.09.028 17081611
55. LeBouder E Rey-Nores JE Rushmere NK Grigorov M Lawn SD Affolter M Griffin GE Ferrara P Schiffrin EJ Morgan BP Labéta MO Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk J Immunol 2003, 171:6680-6689. 14662871
56. Iwami KI Matsuguchi T Masuda A Kikuchi T Musikacharoen T Yoshikai Y Cutting edge: Naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling J Immunol 2000, 165:6682-6686. 11120784
57. Peters RP van Agtmael MA Danner SA Savelkoul PH broucke-Grauls Vanden CM New developments in the diagnosis of bloodstream infections Lancet Infect Dis 2004, 4:751-760. 10.1016/S1473-3099(04)01205-8 15567125
58. Cleven BE Palka-Santini M Gielen J Meembor S Kronke M Krut O Identification and characterization of bacterial pathogens causing bloodstream infections by DNA microarray J Clin Microbiol 2006, 44:2389-2397. 1489523 16825354 10.1128/JCM.02291-05
59. Maquelin K Kirschner C Choo-Smith LP Ngo-Thi NA van Vreeswijk T Stammler M Endtz HP Bruining HA Naumann D Puppels GJ Prospective study of the performance of vibrational spectroscopies for rapid identification of bacterial and fungal pathogens recovered from blood cultures J Clin Microbiol 2003, 41:324-329. 149588 12517868 10.1128/JCM.41.1.324-329.2003